
Travere Therapeutics, Inc. (NASDAQ:TVTX) shares are trading higher on Wednesday after the company announced that it was informed by the FDA that an advisory committee is no longer needed following further review of its supplemental New Drug Application (sNDA) for FILSPARI in focal segmental glomerulosclerosis.
What To Know: The FDA said Travere's sNDA for FILSPARI remains under review with a Prescription Drug User Fee Act target action date of Jan. 13, 2026. FILSPARI would become the first approved treatment for FSGS if approved.